Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04535713
Title Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Oncology Research Center, LLC
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.